enrolment
[용어속성] Action
Prospective cohort study of children with suspected SARS-CoV-2 infection presenting to paediatric emergency departments: a Paediatric Emergency Research Networks (PERN) Study Protocol
Observational Study
[키워드] acute SARS-CoV-2 infection
and ambulatory care
approval
association
asymptomatic infections
benefit
Care
characterisation
children
cohort study
collected
contribute
country
COVID-19
Critical care
E
Emergency
enrolment
epidemiological
Epidemiology
Ethics
Follow-up
global effort
hospitalisation
hospitalised
identify
immunisation
implementation
increased risk
Infant
Infection
Infectious disease
Inflammatory
information
Intensive
interim analysis
International
Laboratory
Mild
National
network
outcome
outcomes
paediatric A&
paediatric infectious disease &
Paediatric intensive &
presenting
Prospective
prospective cohort study
reduce
risk
risk factor
SARS-COV-2 infection
SARS-CoV-2 test
severe COVID-19
Site
study participation
syndrome
tested
those with comorbidity
Viral transmission
Weekly
WHO
[DOI] 10.1136/bmjopen-2020-042121 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1136/bmjopen-2020-042121 PMC 바로가기 [Article Type] Observational Study
Hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care setting (LIBERTY): A structured summary of a study protocol for a randomised controlled trial
일차 진료 환경(LIBERTY)에서 Covid-19 감염 성인 환자 치료에 사용되는 하이드록시클로로퀸: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
addition
addressed
administration
Adult patients
adverse event
adverse events
AEs
age
all-cause hospitalization
Antibody Response
Anxiety
Anxiety Disorder
ARMS
association
Biomarker
blinded
Blinding
Blood
BMI
capture
Care
changes
changes in
Characteristics
clinical trial
concentrations
concomitant medications
conducted
Contact
Course
COVID-19
COVID-19 infection
COVID-19-related symptoms
criteria
death
deleting
Demographic variables
diabetes
Diabetes Mellitus
disease
dissemination
double-blind
Effect
element
enrolment
enzyme
EudraCT
evaluate
exclusion
expected
exploratory
exploratory endpoint
Exploratory endpoints
female
Formulation
GAD-7
Generalized
Generalized Anxiety Disorder
Genetic variation
HCQ
Health care
HLA haplotypes
hospital
Hospitalization
hospitalizations
Hydroxychloroquine
Hypothesis
identify
include
Inclusion
independent
individual
Infection
information
intensive care unit
lactation
masking
mental health
Meta-analysis
Mortality
Nasopharyngeal swab
nasopharyngeal swab sample
Nasopharyngeal swab samples
number
number of deaths
objective
onset of symptom
open care
outcome
Outpatient
outpatients
parallel-group
participant
Patient
patient data
PCR test
PCR testing
PCR-confirmed
Placebo
placebo-controlled
post-hoc
predict
Pregnancy
presenting
primary care
primary endpoint
protocol
public health
public health care
randomised
randomised controlled trial
randomization list
Randomized
Randomly
receive
recruitment
reduce
Registered
Regulation
repeated
reported
respiratory
respiratory distress
respiratory rate
response
risk
room air
SAEs
Sample size
SARS-CoV-2
SARS-CoV-2 PCR test
SARS-CoV-2 viral shedding
Satakunta
secondary endpoint
Secondary endpoints
Secondary objectives
serious AE
serum
Seven
severe pneumonia
severity
specific treatment
status
study participant
Study participants
study population
Study protocol
subgroup analysis
subject
supplementary material
Suspected
Symptom
Symptoms
technology
test result
therapeutic potential
Tolerability
treated
Treatment
treatment allocation
treatment arm
Trial
Trial registration
twice a day
type 1 or type 2
Uppsala
variable
Viral
was performed
website
Well-being
[DOI] 10.1186/s13063-020-04989-6 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04989-6 PMC 바로가기 [Article Type] Letter
SARS-CoV-2 RT-PCR profile in 298 Indian COVID-19 patients: a retrospective observational study
Observational Study
[키워드] age
average
collected
Comorbidities
conducted
COVID
COVID-19
COVID-19 patients
different time points
Elderly patient
eligible
enrolment
first positive
hospital
knowledge
Laboratory
majority
male
nasopharyngeal
New
nucleic acid
oropharyngeal swabs
pandemic
Patient
PCR positivity
PCR test
performed
positive RT-PCR
Positive test
positive test result
profile
profile.
retrieved
retrospective
RT-PCR
SARS CoV-2
SARS-CoV-2
SARS-CoV-2 RT-PCR
statistically significant
symptom onset
symptomatic patient
Treatment
viral dynamics
were excluded
[DOI] 10.1093/femspd/ftaa064 PMC 바로가기 [Article Type] Observational Study
[DOI] 10.1093/femspd/ftaa064 PMC 바로가기 [Article Type] Observational Study
Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial
COVID-19(COVID-AT)로 인한 급성 호흡 곤란 증후군 환자에서 동종 간엽 기질 세포의 효능을 평가하기 위한 이중 맹검, 무작위, 대조 시험: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Letter
[키워드] 1:1
24 hours
7-point ordinal scale
acute respiratory distress
acute respiratory distress syndrome
Administered
administration
Admission
Adult patient
Adult patients
Adverse
Adverse drug reactions
AEs
age
All trial participants
all-cause mortality
allergy
Allogeneic
ARDS
assessment
assigned
baseline
Biomarker
blinded
Blinding
C-reactive protein
carcinoma
carcinoma in situ
carried
cellular
chain
change
childbearing potential
Chloroquine
Clinical practice
clinical status
clinical trial
coagulation test
coagulation tests
conducted
Control
control arm
Course
COVID
COVID-19
CRF
criteria
CT scan
cumulative incidence
current
Cytokines
D-dimer
Day
death
described
determined by
Diagnosis
disease
dissemination
double-blind
drug
Duration
ECMO
Efficacy
Efficacy and safety
element
eligible
End
endpoints
enrolment
EudraCT
evaluate
evaluate the effect
event
exclusion criteria
Extracorporeal
extracorporeal membrane oxygenation
failure
ferritin
fibrosis
FiO2
form
GRADE
grade 3
greater
Haemodialysis
handling
hemofiltration
history
hospital
Hospitalization
hydroxy
ICU
ICU admission
IMPROVE
include
inclusion criteria
Informed consent
intravenous
Intravenous administration
intravenous dose
intubation
Invasive mechanical ventilation
invasive ventilation
investigational medicinal product
involved
laboratory confirmation
laboratory-confirmed SARS-CoV-2 infection
lactation
LDH
less
Level
Local
Lopinavir
Lopinavir/ritonavir
lung disorder
lymphocyte
marker
Mechanical
mechanical ventilation
Medicine
Medicines
Mesenchymal stromal cells
moderate to severe
Mortality
MSC
negative pregnancy test
neoplasm
neutrophil
neutrophil counts
Non-invasive
number
objective
occur
off-label
opinion
Ordinal Scale
organ
oropharyngeal swab
oropharyngeal swabs
Other
outcome
oxygen
oxygen saturation
Oxygen therapy
PaO2
PaO2/FiO2 ratio
parameters
participant
Patient
PCR
percentage
Placebo
polymerase chain reaction
Pregnancy
primary endpoint
product
Production
profile
progression
protocol
Pulmonary embolism
pulmonary fibrosis
Pulmonary function tests
randomised
randomised controlled trial
randomization
Randomized
Randomly
Rapid antigen tests
reaction
receive
recruitment
Registered
Remdesivir
report
respiratory
Respiratory distress syndrome
Resuscitation
Ritonavir
SAEs
Sample size
SARS-COV-2 infection
secondary
Secondary endpoints
Sequential Organ Failure Assessment
Serious Adverse Events
SOFA
Spain
specificity
specimen
Sponsor
Standard of care
status
stromal cell
stromal cells
Study protocol
subpopulations
supplemental oxygen
supplementary material
syndrome
the cell
the disease
the patient
the primary endpoint
the WHO
time
Tocilizumab
Tolerability
Treatment
treatment arm
treatment for COVID-19
treatment group
Treatment protocol
Trial
trial participant
Trial registration
unit
website
women
worldwide pandemic
written consent
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04964-1 PMC 바로가기 [Article Type] Letter
Recombinant human C1 esterase inhibitor (conestat alfa) in the prevention of severe SARS-CoV-2 infection in hospitalized patients with COVID-19: A structured summary of a study protocol for a randomized, parallel-group, open-label, multi-center pilot trial (PROTECT-COVID-19)
입원한 COVID-19 환자의 중증 SARS-CoV-2 감염 예방을 위한 재조합 인간 C1 에스테라제 억제제(conestat alfa): 무작위, 병렬 그룹, 공개 라벨, 다중 센터에 대한 연구 프로토콜의 구조화된 요약 파일럿 시험(PROTECT-COVID-19)
Letter
[키워드] 24 hour
24 hours
Activation
activities
acute lung injury
addition
adjusted
Administered
administration
allergy
Antibiotics
anticipated
anticoagulation
arterial
Arterial hypertension
Basel
Blinding
BMI
Brazil
Breast
Breast feeding
breathing ambient air
C-reactive protein
C1 esterase inhibitor
cardiovascular disease
Caregivers
changes in
Chest
Child-Pugh score
chronic
chronic pulmonary disease
chronic renal disease
cirrhosis
class
clinical
Clinical improvement
clinical trial
comparator
comparator Patients
complement
complement system
completion
conducted
Conestat alfa
Contact
contact activation system
contraindication
control group
Corticosteroids
COVID-19
COVID-19 patient
CT scan
death
defined
discharge
disease
disease severity
dissemination
drug
Duration
Efficacy and safety
element
eligibility
enrolment
evidence of
experimental arm
family members
FIVE
followed by
history
hospital
Hospitalization
hospitalized patient
hypertension
ICU
IL-6 inhibitor
IL-6R
improvement
Incapacity
include
inclusion criteria
individual
Infection
inflammatory cascade
inflammatory cascades
inflammatory proteins
inhibitor
Interactive Web Response System
interim analysis
Intravenous injection
invasive
invasive or non-invasive ventilation
investigator-initiated
investigators
kallikrein kinin system
laboratory parameter
Liver cirrhosis
Local
Lung injury
mechanical ventilation
non-invasive ventilation
not blinded
number
obesity
objective
Open-label
open-label trial
Ordinal Scale
outcome
outcome assessor
outcome assessors
oxygen
oxygen saturation
pandemic
PaO
parallel-group
participant
Participants
Participation
Patient
performed
Pregnancy
primary endpoint
progression
proportion
protocol
pulmonary disease
pulmonary involvement
randomised
randomization
Randomized
randomized trial
receive
recombinant
recruited
recruitment
Registered
Remdesivir
renal
renal disease
required
risk factor
Sample size
SARS-COV-2 infection
SARS-CoV-2 pandemic
scale
screened
secondary
Secondary outcomes
severe COVID-19
severe SARS-CoV-2
Standard of care
status
Study protocol
subject
supplemental oxygen
supplementary material
suspicion
Switzerland
Symptom
the SARS-CoV-2
the WHO
their family members
Tocilizumab
Treatment
treatment arm
Trial
Two interim analyses
Two interim analysis
virological clearance
website
WHO
WHO ordinal scale
with COVID-19
X-ray
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04976-x PMC 바로가기 [Article Type] Letter
Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial
중등도에서 중증의 COVID-19(NACOVID) 치료를 위한 nitazoxanide + atazanavir/ritonavir의 효능 및 안전성: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Comparative Study
[키워드] 1:1
24 hour
24 hours
achievement
addition
Administered
African
age
allocation
anticipated
antiretroviral drugs
antiviral activity
approval
Atazanavir
atazanavir/ritonavir
Blinding
Care
clinical
Clinical improvement
Clinical management
Comorbidities
confirmation
Control
control group
COVID-19
COVID-19 diagnosis
COVID-19 infection
criteria
defined
determined by
diagnosed
Diagnosis
discharge
dissemination
drug
Drug administration
drugs
Efficacy and safety
element
eliminated
enrolment
exclusion criteria
food
Food and Drug Administration
Gender
group
hospital
hypersensitivity
include
inclusion criteria
Infectious diseases
information
initiation of treatment
Interaction
intervention group
Isolation
lactating
mechanical ventilation
medication
moderate
moderate to severe
multicentre
Nasopharyngeal swab
negativity
Nigeria
nitazoxanide
number
objective
Ogun
once daily
Open-label
open-label trial
Ordinal Scale
outcome measure
Pan
Pan African Clinical Trials Registry
participant
Patient
PCR
PCR test
Phase 2
physician
polymerase chain
polymerase chain reaction
positive
pregnant
Proportion of participant
protocol
quantified
randomisation
randomised
randomised controlled trial
receive
receiving
recruited
REDCap
Registered
registry
reported
Ritonavir
RT-PCR
Saliva
Sample size
SARS-CoV-2
SARS-COV-2 infection
SARS-CoV-2 PCR
SARS-CoV-2 polymerase chain reaction
SARS-CoV-2 viral load
secondary care
sequence
severe COVID-19
specialist
Standard
Standard of care
state
Stratification
Study protocol
supplementary material
symptomatic
Teaching
Temporal
the WHO
time
Treatment
Trial
Trial registration
university
Viral
Viral load
website
working
[DOI] 10.1186/s13063-020-04987-8 PMC 바로가기 [Article Type] Comparative Study
[DOI] 10.1186/s13063-020-04987-8 PMC 바로가기 [Article Type] Comparative Study
Chloroquine nasal drops in asymptomatic & mild COVID-19: An exploratory randomized clinical trial
Randomized Controlled Trial
[키워드] 1:1
Administered
administration
adverse event
Analysis
analyzed
ARMS
Asymptomatic
asymptomatic patient
Chloroquine - COVID-19
clinical
Control
COVID-19
COVID-19 infection
cycle threshold
demonstrated
Efficacy and safety
enrolment
exploratory
eye drop
False-positive
greater
indicated
Infection
intervention arm
Local
measure
Mild
mild COVID-19 illness
modified intention-to-treat
nasal
nasal drop
nasal drops
National Early Warning Score
outcome
Patient
patients
prevention of COVID-19
progression
Prophylaxis
proportion
randomization
Randomized
randomized clinical trial
receiving
reducing
RT-PCR
Sample size
SARS CoV-2
score
Seven
significant difference
standard treatment
Supportive treatment
tissue
Treatment
Trial
uninfected
Viral load
Virological
was done
were excluded
were measured
[DOI] 10.4103/ijmr.IJMR_3665_20 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.4103/ijmr.IJMR_3665_20 PMC 바로가기 [Article Type] Randomized Controlled Trial
Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial
성인의 중증 COVID-19 치료를 위한 분무형 계면활성제(COV-Surf): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약
Randomized Controlled Trial
[키워드] 1080
24 hour
24 hours
48 hour
48 hours
ACE2
ADEs
administration
Adverse
adverse event
adverse events
AEs
ALEA
All participant
All participants
allergy
alveolar
angiotensin
angiotensin converting enzyme
angiotensin converting enzyme 2
anticipated
attending physician
bind
Blinding
block randomization
Blood
bovine
breath
buffer
calcium
cells
cellular
cholesterol
Chronic kidney disease
class
clinical
Clinical improvement
clinical trial
clinical trials
Cohort
Combination
comparator
Compliance
Concentration
conducted
Consent
contraindication
contributing to
Control
control arm
controls
COVID-19
COVID-19 adult patient
COVID-19 patients
current
cytokine
Data collection
Data monitoring committee
death
declined
defined
delivery
described
Device
dialysis
discretion
dissemination
dose
drug
Effect
Efficacy
EGFR
element
Eligible participants
end point
End-Expiratory Pressure
Endotracheal intubation
enrolled
Enrollment
enrolment
epithelial
Escalation
EudraCT
evaluate
exclusion
exclusion criteria
expected
fatty
Fatty acid
feasibility
free fatty acid
Frequency
hospital
hospitalised
hypoxia
impair
include
inclusion criteria
index
Inflammatory marker
inflammatory markers
Inflammatory response
intensive care
intensive care unit
Intervention
investigator
Kidney disease
lack
liver
liver failure
Local
lung
lung lavage
mechanical ventilation
mechanical ventilator
mechanically ventilated patient
mechanically ventilated patients
mixture
Mortality
nebulisation
number
objective
Open-label
opinion
Ordinal Scale
other treatment
outcome
oxidative stress
Oxygenation
PaO
participant
Patient
PCR
PEEP
Phosphatidylcholine
phosphatidylethanolamine
phosphatidylglycerol
phosphatidylinositol
phospholipid
PIP
Placebo
plasma
Pneumothorax
Positive end-expiratory pressure
Prevent
Primary outcome
progression
Protein
protocol
pulmonary compliance
pulmonary hemorrhage
pulmonary ventilation
quantification
randomisation
randomised
randomised controlled trial
Randomized
Randomized controlled trial
reached
receive
recorded
recruitment
reduction
Registered
reported
Respiratory failure
SAEs
Sample size
SARS-CoV-2 viral load
SARS-CoV-2 virus
secondary outcome
Secondary outcomes
Serious Adverse Events
severe COVID-19
severity
sphingomyelin
Stage
Standard
Standard of care
status
Study protocol
subject
supplementary material
surface tension
surfactant
synthesis
tension
the WHO
tissue damage
total sample size
tracheal
tracheal aspirate
Tracheal aspirates
transfer
Treatment
Trial
Trial Steering Committee
turnover
unique
university
University College London
usual standard of care
Ventilation
Ventilation Index
ventilatory support
VFD
vibrating mesh nebulizer
Viral
Viral load
virus
water
website
weight
with COVID-19
worsening
[DOI] 10.1186/s13063-020-04944-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
[DOI] 10.1186/s13063-020-04944-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and efficacy of herbal extracts to restore respiratory health and improve innate immunity in COVID-19 positive patients with mild to moderate severity: A structured summary of a study protocol for a randomised controlled trial
Letter
[키워드] 1:1
administer
Administered
allergic
Analysis
Asparagus
automatically
Ayurveda
CAM
CAP
Capsule
clinical
coded
COVID
COVID 19
COVID-19
COVID-19 positive patient
CTRI
Date
declining
dissemination
Dizziness
dose
double blind
drop-outs
early recovery
Efficacy
element
eligible
Embelia
enrolled
enrolment
exploratory
Follow-up
function
ginger
glycyrrhiza
Health
health condition
Herbal
Herbo-mineral
IL6
IMPROVE
in viral
India
Infection
Innate immunity
Intervention
intervention group
investigator
Last
Medicine
Memorial
Mild
moderate
number
objective
outcome
parallel group
participant
Patient
patients with COVID-19
positive
positive patient
positive RT-PCR
product
protocol
racemosus
randomised
randomised controlled trial
Randomized
Rash
recruitment
reducing
Registered
registration number
registry
Safe
Safety
Sample size
screened
secondary
Shankha
status
study period
Study protocol
submission
Test
Th17
the disease
the placebo group
Treatment
Trial
two group
two groups
Viral load
website
were blinded
Zinc
Zingiber
[DOI] 10.1186/s13063-020-04906-x PMC 바로가기 [Article Type] Letter
[DOI] 10.1186/s13063-020-04906-x PMC 바로가기 [Article Type] Letter